AstraZeneca Signs US$1.77 B Renal Disease Licensing Pact with CSPC Pharmaceutical Group
By Nikita Negi
Pharma Deals Review: Vol 2026 Issue 7 (Table of Contents)
Published: 20 Jul-2026
DOI: 10.3833/pdr.v2026.i7.3024 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In an effort to expand its presence in renal diseases and strengthen its nucleic acid therapeutics pipeline, AstraZeneca has signed a collaboration, option and license agreement with CSPC Pharmaceutical Group to develop a novel small nucleic acid drug candidate for kidney disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS